GEHC
GE HealthCare Technologies Inc.
GEHC's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over GEHC overall, supported by stronger fundamentals and stronger modeled upside.
GEHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
GEHC's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
GEHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $71.95 | -12% |
| Forward | 15x | $81.84 | — |
| Current | 17x | $81.84 | — |
| Fair | 19x | $87.98 | +7.5% |
| Expensive | 24x | $111 | +36% |
Historical ranges are pointers, not guarantees.
GEHC has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
GEHC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for GEHC, with profitability improving.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
GEHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.35 | +13% |
| Q3 2026 | $4.73 | -2.5% |
| Q2 2026 | $4.35 | -11% |
| Q1 2026 | $4.17 | -12% |
| Q4 2025 | $4.55 | +4.8% |
| Q3 2025 | $4.85 | +33% |
| Q2 2025 | $4.89 | +42% |
| Q1 2025 | $4.76 | +39% |
| Q4 2024 | $4.34 | +43% |
GEHC earned $4.73 per share over the past year, down 2.5% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over GEHC on earnings, with more consistent year-over-year improvement.
GEHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.5B | +7.2% |
| Q2 2026 | $5.3B | +5.8% |
| Q1 2026 | $5.1B | +7.4% |
| Q4 2025 | $5.7B | +7.1% |
| Q3 2025 | $5.1B | +5.8% |
| Q2 2025 | $5B | +3.5% |
| Q1 2025 | $4.8B | +2.7% |
| Q4 2024 | $5.3B | +2.2% |
GEHC's revenue has grown year over year for 10 quarters in a row: $5.5B last quarter, up 7.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | +1.9 points |
| Q2 2026 | 14% | +0.9 points |
| Q1 2026 | 10% | -3.1 points |
| Q4 2025 | 15% | -0.6 points |
| Q3 2025 | 13% | -1.2 points |
| Q2 2025 | 13% | +0.5 points |
| Q1 2025 | 13% | +1.6 points |
| Q4 2024 | 15% | +1.8 points |
GEHC's operating margin was 15% last quarter, up 1.9 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over GEHC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over GEHC on profitability, with a higher operating margin.
GEHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $793M | +64% |
| Q2 2026 | $68M | +750% |
| Q1 2026 | $112M | +14% |
| Q4 2025 | $916M | +13% |
| Q3 2025 | $483M | -26% |
| Q2 2025 | $8M | +$191M |
| Q1 2025 | $98M | -64% |
| Q4 2024 | $811M | -15% |
GEHC generated $1.9B in free cash flow over the past year, up 35% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over GEHC on cash flow, with more consistent year-over-year improvement.
GEHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -1M shares |
| 1 year | -0.9% | -4M shares |
| 3 years | -1.1% | -5M shares |
| 5 years | -0.4% | -1.7M shares |
GEHC has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $200M |
| Q1 2026 | $100M |
| Q4 2025 | — |
| Q3 2025 | $100M |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
GEHC spent $300M buying back its own shares over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
GEHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.0x | Moderate |
| Q2 2026 | 2.4x | Moderate |
| Q1 2026 | 2.4x | Moderate |
| Q4 2025 | 1.8x | Healthy |
| Q3 2025 | 2.5x | Moderate |
| Q2 2025 | 2.6x | Moderate |
| Q1 2025 | 2.5x | Moderate |
| Q4 2024 | 2.4x | Moderate |
GEHC's net debt is about 2.0 years of its operating earnings (EBITDA), down from 2.5 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over GEHC on leverage, with a lower net debt burden relative to earnings.
GEHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.0 | Neutral |
| Stochastic | 82.0 | Overbought |
GEHC's weekly RSI is 65 (neutral) and its Stochastic is 82 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
GEHC PE vs Healthcare Sector
| Metric | GEHC | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 26x | 33% below |
| PE % | 42 | 42 | Same percentile |
GEHC has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
GEHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.3 | 13% above |
| 20 week MA | $69.5 | 18% above |
| 50 week MA | $72.1 | 13% above |
| 100 week MA | $74.2 | 10% above |
| 200 week MA | $76.6 | 6.9% above |
GEHC has climbed back above all five of its weekly moving averages, and it's now 6.9% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
GEHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $58.4 | $77.3 | +32% |
| 2024 | $77.3 | $79.5 | +2.8% |
| 2025 | $79.5 | $83.6 | +5.2% |
| 2026 YTD | $83.6 | $81.8 | -2.1% |
GEHC has finished every year since 2023 higher, and it's down 2.1% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over GEHC on returns for 2026, with the stronger performance.